Melbourne, Australia – 11 February 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce it has completed the first production run of the next generation Hailie® sensors with physiological parameters for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD) medication use.
Mr Rick Legleiter, Chief Executive Officer, commented, “commencing manufacturing of our new, next generation smart inhaler is an important milestone. This is another example of executing and delivering on our product roadmap. Bringing innovation to market and working with our business partners to implement and deliver value-based medicine is the path toward commercializing our product portfolio. As a respiratory innovator for over 20 years, Adherium has an unequalled and formidable track record of development and experience expected of a market leader in respiratory digital health.”
Adherium’s newest FDA 510(k) cleared Hailie for Symbicort sensor, which was engineered specifically for use with AstraZeneca’s market leading aerosol inhaler, has commenced manufacturing and completed the first production run at its contract manufacturing partner facility in SE Asia.
United States Centers for Medicare & Medicaid Services (CMS) reimbursement under the Remote Physiologic Monitoring CPT® codes encourages and financially supports the market adoption of technological innovation in digital health. The addition of physiological parameters to the Hailie range of products enhances the opportunity for remote patient monitoring services. This is especially valuable when managing severe, uncontrolled and difficult to treat Asthma and COPD patients. This U.S. patient group is estimated to represent a total addressable market of US$1.5 billion.
The Hailie for Symbicort sensor with physiological parameters is the first in a series of devices specifically designed to enable physicians and providers to improve patient care and clinical workflow by capturing advanced data supporting patient management and treatment.
“This new Hailie for Symbicort sensor is the first in our new range of digital smart inhalers that will be delivered over the next 12 months,” said Geoff Feakes, Adherium’s Chief Technology Officer. “These next generation sensors deliver physiological parameters including inhalation duration, inhalation volume, and peak inhalation flow in addition to the existing monitoring of device activation timing and frequency. Adherium expects to deliver on its technology roadmap and expand our estimated Asthma and COPD coverage of the addressable market U.S. from 50% to over 80% including 18 inhaled medications. This enables Asthma and COPD sufferers to be better managed with carers receiving data of their medication usage, device technique and understanding of their disease status from one device for the first time”.
“Physiological parameters have been consistently identified as a key data set for the patient population to benefit from this state-of-the-art technology”, Feakes added.
In addition to Hailie sensors, Adherium’s product portfolio goes beyond medical devices to include an integrated digital platform comprised of the Hailie apps, online interface portals, third-party software interface architecture, data management and analytics cloud. The Company is continuing to invest in advanced development, updates and enhancements of the digital infrastructure required of a respiratory digital health leader.